DrugSyn-LLM: LLM Systems for Drug Discovery

• DrugSyn-LLM is a systems paradigm that inserts LLMs between high-level queries and structured biomedical representations to ensure rational, constraint-bound outputs.
• It enhances applications such as natural language database querying, formulation design, drug interaction prediction, and molecular generation through domain-adapted prompts and representations.
• By integrating retrieval, reinforcement learning, and fine-tuning, DrugSyn-LLM grounds language model outputs in chemical and pharmacological constraints for actionable insights.

DrugSyn-LLM (Editor's term) denotes a class of large-language-model systems for drug discovery and pharmacology in which the model serves as an interface, reasoning module, or decision engine over structured biomedical resources rather than as a standalone text generator. In the cited literature, this pattern appears in natural-language querying of pharmacology databases, solid dosage formulation design, drug-combination interaction classification, drug-drug interaction prediction, few-shot molecule generation, explicit-reasoning molecular optimization, automatic target-dossier construction, and route-level synthesis planning (Lu et al., 2023, Lin et al., 14 Mar 2025, Surana et al., 28 Dec 2025, Vito et al., 9 Feb 2025, Liu et al., 2024, Liu et al., 9 Feb 2026, Fossi et al., 2024, Wang et al., 11 May 2025). A plausible implication is that DrugSyn-LLM is best understood as a systems paradigm for grounding LLM behavior in pharmacological structure, experimental constraints, and external tools.

1. Architectural pattern and representational strategy

Across these systems, a recurring design choice is to place an LLM between a high-level user request and an operational intermediate representation. In the pharmacology-database interface, the intermediate object is SQL produced after named entity recognition, entity linking, placeholder substitution, schema linking, question decomposition, Chain-of-Thought, and self-correction. In formulation design, the model receives structured prompts containing role specification, background scientific context, explicit task instructions, input-format constraints, output-format requirements, and scientific constraints such as the Nernst-Brunner dissolution model. In few-shot molecule generation, molecules are converted into Group-based Molecular Representation (GMR) sequences and organized into “modification paragraphs.” In DrugR, the output is explicitly bifurcated into a reasoning segment and an optimized SMILES segment. In route-level synthesis planning, entire retrosynthetic trajectories are serialized as linear stepwise decisions containing the current molecule set, Rational, Product, Reaction, generated Reactants, and Updated molecule set (Lu et al., 2023, Lin et al., 14 Mar 2025, Liu et al., 2024, Liu et al., 9 Feb 2026, Wang et al., 11 May 2025).

This architectural convergence matters because it reduces the burden on pure free-form generation. The cited systems repeatedly rely on typed placeholders, JSON-like schemas, raw-text prompts with fixed field ordering, GMR tokens, route encodings, retrieval contexts, or reward-balanced objectives. This suggests that the decisive engineering problem in DrugSyn-LLM is not merely scaling a foundation model, but constructing representations that preserve chemical, pharmacological, and workflow constraints while remaining accessible to autoregressive language modeling.

2. Natural-language interfaces to pharmacology databases

A canonical DrugSyn-LLM-style system is the LLM-based natural language interface for pharmacology databases in “Utilizing LLMs for Natural Interface to Pharmacology Databases” (Lu et al., 2023). Its motivation is the practical difficulty of querying heterogeneous biomedical databases containing genes, proteins, drugs, phenotypes, diseases, pathways, and their relations when the end user does not know SQL or the underlying schemas. The system is intended to let domain users ask questions such as “What are the key biological processes in which protein ADD1 is involved?” or “Are there any known phenotypes associated with mutations or dysfunctions in protein KRAS?” without manually crafting SQL.

The architecture has two pipelines. In the question-answering pipeline, a user question is processed by an in-house named entity recognition model, passed through an entity linker built on Cognitive Search, normalized by replacing detected entities with type-aware placeholders, sent to GPT-4 as the SQL generator, executed against the database, and returned as a database-grounded answer. GPT-4 is described as handling schema linking, question decomposition, Chain-of-Thought reasoning, and self-correction. The separate question-generation pipeline is used both to synthesize evaluation data and to provide in-context demonstrations for few-shot question answering, with the explicit goal of generalizing across different pharmacology databases and query patterns (Lu et al., 2023).

The exemplar backend is PrimeKG, described as a comprehensive biomedical knowledge graph containing 10 types of entities, 30 types of relations, and more than 8 million edges aggregated from 20 biomedical data sources. The paper presents the interface as applicable not only to PrimeKG but also to public or private databases and, more generally, to “a wide range of pharmaceutical data and knowledge bases” that can be exposed through SQL (Lu et al., 2023).

The evaluation combines synthetic and realistic datasets. The synthetic dataset contains 60 single-hop questions and 204 two-hop questions generated from the knowledge graph and reviewed by domain experts. The realistic dataset contains 50 question-answer pairs curated by experts who were not aware of the database schema. Using Exact Match (EM) and F1-score, GPT-4 with the full pipeline achieves EM 0.708 and F1 0.712 on the realistic dataset. Removing self-correction leaves performance unchanged in the reported GPT-4 setting, while removing NER and using oracle entity names increases performance to EM 0.792 and F1 0.797. On the synthetic dataset, the full setting achieves overall EM 0.378 and F1 0.350, with 0.450/0.496 on single-hop and 0.320/0.343 on two-hop; removing NER and using oracle entity names improves overall performance to EM 0.513 and F1 0.543 (Lu et al., 2023).

The central significance of these results lies in where the bottleneck appears. SQL generation itself is presented as feasible and effective, whereas upstream entity handling is explicitly identified as the main source of end-to-end error. The harder performance on two-hop questions further indicates that compositional reasoning remains a substantive difficulty even when the LLM is coupled to a structured backend.

3. Prompt-engineered formulation design and pharmaceutical process development

A second major instantiation of DrugSyn-LLM is prompt-engineered solid dosage formulation design. “DeepSeek Powered Solid Dosage Formulation Design and Development” uses DeepSeek-R1-671b as a reasoning and design engine for dissolution-profile prediction and inverse design of physical attributes such as particle size distribution (PSD), aspect ratio, and specific surface area (Lin et al., 14 Mar 2025). The model is not treated as a mere text generator. It is asked either to predict “Drug Released (%)” over time from particle- and material-level properties or to invert the problem and propose property settings that would yield a target dissolution behavior.

The prompts are structured and domain-constrained. They contain role specification, background scientific context, explicit task instructions, input-format constraints, and output-format requirements, and they encode physicochemical relationships such as the Nernst-Brunner dissolution model and radial diffusion concepts. The evaluated prompting strategies are zero-shot, zero-shot-CoT, few-shot, few-shot-CoT, and RAG. The zero-shot prompt is a structured JSON-style request with fields such as D50, aspect ratio, roundness, solubility, diffusion coefficient, density, SSA, and particle size, plus the requirement that final dissolution should be at least 85% within 60 min. Few-shot prompting adds real experimental examples from Salish et al., while RAG retrieves external scientific sources and FDA dissolution databases to ground outputs (Lin et al., 14 Mar 2025).

Validation uses literature data and real experimental data from the authors’ lab. Dissolution experiments are run with the USP II paddle method in phosphate buffers at pH 7.2 and pH 6.2; drug concentration is measured by UV-vis spectrometry; each sample is tested in five replicates. The quantitative results are reported with MSE and $R^2$: zero-shot gives MSE $= 23.61$ and $R^2 = 0.97$; zero-shot-CoT gives MSE $= 114.89$ and $R^2 = 0.90$; few-shot gives MSE $= 57.0$ and $R^2 = 0.92$; few-shot-CoT gives MSE $= 22.56$ and $R^2 = 0.97$; and RAG gives the best result, MSE $= 10.55$ and $= 23.61$0 (Lin et al., 14 Mar 2025).

The section’s most important conceptual point is that reasoning scaffolds are not uniformly beneficial. The paper explicitly reports that zero-shot-CoT degrades performance, attributing this to ungrounded step-by-step reasoning that may introduce hallucinations, whereas few-shot-CoT improves accuracy because the reasoning is anchored to concrete examples. This directly challenges the common assumption that Chain-of-Thought is automatically advantageous in pharmaceutical engineering workflows.

4. Interaction prediction: synergy labels, multi-drug histories, and binary DDIs

DrugSyn-LLM also encompasses LLM-based prediction of drug combination effects. MixRx formulates the task as classification of a multi-drug combination into Additive, Synergistic, or Antagonistic from a patient’s multi-drug history and related interaction context (Surana et al., 28 Dec 2025). In the SynergxDB setup, the input includes combinations of 2 to 5 drugs together with pairwise synergy scores based on Loewe, Bliss, HSA, and ZIP. The paper describes the mapping in functional form as

$= 23.61$1

Its illustrative prompt includes a Loewe-threshold rule: if Loewe $= 23.61$2, predict Antagonistic; if Loewe $= 23.61$3, predict Synergistic; otherwise, predict Additive (Surana et al., 28 Dec 2025).

The study evaluates GPT-2, GPT-2 fine-tuned, Mistral-7B-Instruct-v0.2, and Mistral-7B-Instruct-v0.2 fine-tuned. SynergxDB contains 10,000 valid drug combinations of length 2 to 5, split 80/10/10 train/test/validation. A perturbed “SynergxDB, Messy” version simulates emergency-medicine noise by either swapping two letters in a drug name or deleting the last letter. The strongest reported result is from the fine-tuned Mistral model, which achieves an average accuracy of 81.5% across the standard and perturbed datasets. On the standard set, Mistral FT reports Precision 1.00, Recall 0.82, F1 0.90, Accuracy 0.82, ROUGE-1 0.5288, ROUGE-L 0.4664, and BLEU 0.3614; on the messy set, the corresponding values are Precision 1.00, Recall 0.81, F1 0.90, Accuracy 0.81, ROUGE-1 0.5175, ROUGE-L 0.4515, and BLEU 0.3489 (Surana et al., 28 Dec 2025).

A related but distinct line of work addresses binary drug-drug interaction prediction. “LLMs for Drug-Drug Interaction Prediction: A Comprehensive Comparison” represents each ordered drug pair as raw text including drug name, SMILES, target organism(s), and target-gene information, with an explicit instruction that order of administration counts (Vito et al., 9 Feb 2025). Its main benchmark source is DrugBank, which is reported to contain 16,581 drugs, about 3,921 unique target genes, and 1,420,072 known DDIs. After filtering, the authors retain 1,035,150 positive interactions and construct a balanced dataset of 2,070,300 pairs. External validation uses 13 usable datasets totaling 21,947 unique DDIs from the Ayvaz et al. collection (Vito et al., 9 Feb 2025).

The paper evaluates 18 LLMs in zero-shot mode and fine-tunes five of them. Zero-shot performance is only moderate, with an average sensitivity of 0.5463 reported in the abstract/discussion, but fine-tuning changes the picture substantially. The headline result is that Phi-3.5 2.7B achieves sensitivity 0.978 and accuracy 0.919 on balanced datasets. Across the 13 external datasets, the reported average sensitivity values are 0.978 for Phi-3.5 3B, 0.975 for Qwen2.5 3B, 0.953 for DeepSeek Qwen 1.5B, 0.933 for GPT-4o, and 0.925 for the reproduced l2-regularized logistic-regression baseline of Mei and Kun Zhang (Vito et al., 9 Feb 2025).

Taken together, these two papers show two distinct formulations of interaction modeling: one multiclass and combination-oriented, one binary and pairwise but explicitly directional. They also support a broader conclusion that fine-tuning and prompt design matter more than generic pretraining alone, and that smaller adapted models can outperform much larger untuned systems.

5. Molecular generation and explicit-reasoning optimization

In molecular design, DrugSyn-LLM spans both few-shot generative modeling and explicit-reasoning optimization. DrugLLM is a 7B-parameter LLaMA-style Transformer decoder trained for few-shot molecule generation using Group-based Molecular Representation (Liu et al., 2024). GMR is motivated by three stated limitations of SMILES for LLM training: token abundance, cyclic complexity, and structural sensitivity. Molecules are decomposed into structural groups, and inter-group connectivity is encoded with a slash-separated format,

$= 23.61$4

Training data are not isolated molecules but “modification paragraphs” of the form

$= 23.61$5

where all modification cases in the paragraph correspond to the same property/task. The autoregressive objective is

$= 23.61$6

and inference is defined for few-shot optimization as

$= 23.61$7

and for zero-shot instruction-guided optimization as

$= 23.61$8

The corpus is large: ZINC contributes 4.5M molecules, 0.6M paragraphs, and 770 tasks; ChEMBL contributes 180.2M molecules, 24M paragraphs, and 10,100 tasks; in aggregate the paper summarizes this as over 25 million modification paragraphs and over 200 million molecules (Liu et al., 2024).

The reported results indicate strong few-shot behavior. For physicochemical optimization, baseline methods such as JTVAE, VJTNN, MoLeR, and random generation are around 50% success, whereas DrugLLM improves with more shots and reaches about 75% success for LogP. For ten held-out biological activities, DrugLLM attains an average success rate of 0.68 versus 0.51 for Random, 0.54 for JTVAE, 0.46 for VJTNN, and 0.53 for MoLeR. On zero-shot instruction-guided tasks, DrugLLM outperforms ChatGLM, ChatGPT, and GPT-4 across all six reported property-composition settings, with success rates from 0.40 to 0.61 (Liu et al., 2024).

DrugR moves from few-shot generation to explicit reasoning-driven molecular optimization (Liu et al., 9 Feb 2026). Starting from LLaMA-3-8B-Instruct, it applies domain-specific continual pretraining on ChemicalQA (~150K), MoleculeNet (~160K), UltraChat-200K (~200K), and an internal CPT text corpus (~300K). Because no existing reasoning dataset for drug optimization was available, the authors construct one by reverse data engineering: starting molecules are collected from ChEMBL / DrugBank-derived drug seeds, DeepSeek-R1 generates structurally related candidates, candidates are filtered by fingerprint similarity $= 23.61$9, ADMETLab identifies better and worse molecules, and an LLM generates rationales for the transition. The resulting explicit-reasoning dataset contains 4,855 samples, split 85% / 10% / 5% into 4,126 / 485 / 244 (Liu et al., 9 Feb 2026).

DrugR then combines a two-stage SFT curriculum with self-balanced multi-granular reinforcement learning using GRPO. The reasoning objectives are target-property F1, reasoning LMS score, and reasoning richness; the SMILES objectives are overall optimization score, fingerprint similarity, and binding energy. The paper emphasizes a two-level adaptive self-balancing mechanism consisting of sample-level Pareto-aware reweighting and batch-level group and channel balancing. Constraints include fingerprint similarity $R^2 = 0.97$0 and binding energy lower than $R^2 = 0.97$1 kcal/mol as satisfactory. On the main benchmark, DrugR reports Overall Optimization Score 0.2712, Target property F1 0.4364, Fingerprint Similarity 0.6409, Reasoning LMS 0.7712, and Reasoning richness 0.9877. The ablation without reasoning collapses to Overall Optimization Score 0.0151 and Fingerprint Similarity 0.1297, while the system maintains target affinity with only about 4.1% worsening on average and about 95.84% of generated molecules are “satisfying design” under the paper’s criteria (Liu et al., 9 Feb 2026).

One recurrent misconception is that reasoning traces are merely cosmetic interpretability overlays. DrugR directly contradicts that view: its reported ablations indicate that explicit reasoning is functionally necessary for effective optimization rather than a decorative post hoc explanation.

6. Agentic evidence synthesis and route-level synthesis planning

DrugSyn-LLM also appears in systems where LLMs orchestrate retrieval, tools, and multi-step decision programs. SwiftDossier is an automatic target-dossier system that takes a target gene name and a pathology of interest and produces a PDF target dossier plus a PowerPoint presentation (Fossi et al., 2024). Its motivating example is KRAS in pancreatic cancer, but the workflow is described as generalizable to any gene/pathology pair. The system combines an agent layer with Python code execution, image retrieval, and LLM generation with RAG; its data sources include UniProt, Human Protein Atlas, DrugBank, Open Targets, RCSB PDB, cBioPortal, TCGA Survival, OGEE, STRING, SIGNOR, ESMO, PubChem, NCBI Gene, PubMed, PMC, BLAST, DeepTMHMM, and GSEApy (Fossi et al., 2024).

Its RAG stack uses bge-base-en, fine-tuned on a synthetic pancreatic cancer dataset generated by Qwen 7B, plus mxbai-rerank-large as reranker. PubMed abstracts are directly embedded; PMC full articles are chunked with LangChain SemanticChunker; embeddings are stored in a temporary Chroma DB collection; results are reranked before being passed to the LLM; and PMIDs are preserved for source-level traceability. Evaluated on 22 expert-written drug discovery questions with GPT-4 as judge, the full RAG system is best across faithfulness, relevance, quality, completeness, and correctness: 75% of scores are $R^2 = 0.97$2 for every metric, and the new RAG has median 5 whereas the other two conditions have median 4 (Fossi et al., 2024). The dossier includes target information, disease information, competitive landscape, and conclusion, with subsections such as transmembrane helix prediction, subcellular location, mutations, pathway enrichment, Kaplan–Meier curves, standard of care, known drugs targeting the chosen gene, and SWOT analysis (Fossi et al., 2024).

On the synthesis side, “LLM-Augmented Chemical Synthesis and Design Decision Programs” argues that LLMs are relatively weak as raw single-step retrosynthesis predictors but can become effective route-level planners when combined with structured encodings, retrieval, grounding, and search (Wang et al., 11 May 2025). Retrosynthesis is formalized as repeated decomposition until all remaining molecules are in the purchasable compound set $R^2 = 0.97$3, and the synthesizable design extension is written as

$R^2 = 0.97$4

The method retrieves reference routes by Morgan fingerprints and Tanimoto similarity, generates initial routes, evaluates them at molecule, reaction, and route levels, selects promising candidates by partial reward, and mutates routes using feedback. To reduce hallucinations, proposed reactions are matched against a reaction database by exact match or by retrieving the top 100 similar reactions and retaining the most similar chemically feasible match (Wang et al., 11 May 2025).

Benchmarking covers USPTO Easy, USPTO-190, Pistachio Reachable, and Pistachio Hard, with purchasable building blocks drawn from 23 million eMolecules compounds. Using GPT-4o and DeepSeek-V3 under budgets of 100, 300, and 500 model calls and up to 60 minutes per molecule, GPT-based LLM-Syn-Planner achieves solve rates of 91.0 / 99.5 / 100.0 on USPTO Easy, 64.7 / 91.1 / 92.1 on USPTO-190, and 72.0 / 86.0 / 87.0 on Pistachio Hard (Wang et al., 11 May 2025). The paper’s main claim is therefore not that LLMs are superior local reaction predictors, but that they are effective route planners and synthesis decision engines under structured search.

7. Limitations, failure modes, and research trajectory

Several limitations recur across the DrugSyn-LLM landscape. Grounding remains indispensable. In the pharmacology-database interface, NER and entity linking are explicit bottlenecks, with oracle entity names producing large gains. In formulation design, RAG is the best-performing configuration and zero-shot-CoT is markedly worse than zero-shot. In SwiftDossier, advanced RAG is necessary because vanilla LLMs lack up-to-date and verifiable information. In route-level synthesis planning, reaction grounding to a database is introduced precisely to control hallucinated chemistry (Lu et al., 2023, Lin et al., 14 Mar 2025, Fossi et al., 2024, Wang et al., 11 May 2025).

Validation is also uneven. The realistic pharmacology QA set contains 50 expert-curated question-answer pairs; MixRx reports that NIH Drug Encounter Data experiments were still in progress; DrugR and the synthesis-decision-program paper rely on in silico evaluation rather than wet-lab validation; and the formulation paper explicitly notes that pharmaceutical datasets are scarce, inconsistent, proprietary, and noisy (Lu et al., 2023, Surana et al., 28 Dec 2025, Liu et al., 9 Feb 2026, Lin et al., 14 Mar 2025, Wang et al., 11 May 2025). This suggests that current evidence is strongest for feasibility and systems integration, and weaker for broad clinical or laboratory generalization.

A further misconception is that larger models automatically dominate. The DDI comparison shows that a fine-tuned Phi-3.5 2.7B can achieve sensitivity 0.978 and accuracy 0.919, outperforming many larger models; MixRx shows that fine-tuned Mistral-7B-Instruct-v0.2 clearly surpasses both base Mistral and GPT-2 variants; DrugLLM shows that a chemistry-specialized 7B model can outperform general-purpose LLMs in few-shot and zero-shot molecular optimization (Vito et al., 9 Feb 2025, Surana et al., 28 Dec 2025, Liu et al., 2024). The decisive variables in these studies are domain adaptation, representation choice, retrieval, and evaluation protocol rather than scale alone.

Future directions are correspondingly pragmatic. The pharmacology interface points to stronger entity linking, better multi-hop reasoning, more robust self-correction, and broader database coverage. The formulation study proposes a self-constructed database with 30% real experimental data and 70% simulated data for RAG and extension to flowability and mechanical properties. DrugR identifies finer-grained reward design, stronger evaluators, broader therapeutic scope, and closed-loop wet-lab optimization. The DDI and combination-prediction papers point to better handling of class imbalance, novel compounds, interpretability, and more specialized classification layers (Lu et al., 2023, Lin et al., 14 Mar 2025, Liu et al., 9 Feb 2026, Vito et al., 9 Feb 2025, Surana et al., 28 Dec 2025).

In aggregate, the literature portrays DrugSyn-LLM not as a single model family with one canonical objective, but as a grounded, task-coupled methodology for making LLMs operational in pharmacology and drug discovery. Its defining trait is the repeated insertion of structure—database schemas, prompt constraints, molecule encodings, reward functions, retrieval layers, evaluators, and route search—between language generation and scientific action.